GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Q-linea AB (OSTO:QLINEA) » Definitions » Net-Net Working Capital

Q-linea AB (OSTO:QLINEA) Net-Net Working Capital : kr0.54 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Q-linea AB Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Q-linea AB's Net-Net Working Capital for the quarter that ended in Dec. 2023 was kr0.54.

The industry rank for Q-linea AB's Net-Net Working Capital or its related term are showing as below:

OSTO:QLINEA's Price-to-Net-Net-Working-Capital is ranked better than
66.15% of 455 companies
in the Medical Devices & Instruments industry
Industry Median: 6.46 vs OSTO:QLINEA: 4.07

Q-linea AB Net-Net Working Capital Historical Data

The historical data trend for Q-linea AB's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q-linea AB Net-Net Working Capital Chart

Q-linea AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only 7.55 10.42 5.08 0.97 0.54

Q-linea AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 -1.41 -3.37 0.99 0.54

Competitive Comparison of Q-linea AB's Net-Net Working Capital

For the Medical Instruments & Supplies subindustry, Q-linea AB's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q-linea AB's Price-to-Net-Net-Working-Capital Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Q-linea AB's Price-to-Net-Net-Working-Capital falls into.



Q-linea AB Net-Net Working Capital Calculation

Q-linea AB's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(81.895+0.75 * 0.06+0.5 * 46.527-42.341
-0-0)/116.838
=0.54

Q-linea AB's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2023 is calculated as

Net-Net Working Capital(Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(81.895+0.75 * 0.06+0.5 * 46.527-42.341
-0-0)/116.838
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Q-linea AB  (OSTO:QLINEA) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Q-linea AB Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Q-linea AB's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Q-linea AB (OSTO:QLINEA) Business Description

Traded in Other Exchanges
Address
Dag Hammarskjolds vag 52 A, Uppsala, SWE, SE-752 37
Q-linea AB is a company that develops solutions for improved infectious disease diagnostics. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.

Q-linea AB (OSTO:QLINEA) Headlines

No Headlines